Clinical trials

Combining existing medicines to target aging

Rejuvenate Biomed closes in on €9 million funding round for human trials of sarcopenia-targeted combined drug. Already well-known for its beer and bureaucracy to its...

Longevity marketing and the need for clarity

Dr Oliver Zolman makes the case for Longevity companies adopting a checklist when it comes to making anti-aging claims. When it comes to marketing in...

New immune aging drug brings Longevity and C19 hope

Phase 2-ready drug can treat and reverse immune aging, BioAge claims. BioAge Labs' in-licensed clinical-stage therapy has potential for treating immune aging in older patients...

Longevity trials: time to change the approach?

Leading academic says high profile trial failures should drive changes in how we approach trials for drugs that target aging. Following the recent clinical trial...

Leading academic sees “great promise” in longevity supplements

Buck professor Brian Kennedy talks about AKG and the potential for supplements to deliver real anti-aging benefits. Following Tuesday’s news from the Buck Institute about...

AKG study first to show “dramatically compressed” morbidity in mammals

The Buck's new peer-reviewed study of alpha-ketoglutarate shows a significant reduction in frailty in older mice, resulting in compression of late-life morbidity. The Buck Institute...

Healthy aging – it’s still all about diet and exercise. For now

As Healthy Aging Month arrives, Dr Thomas Rando shares his views on progress in Longevity science. For the past two decades, September has been celebrated...

$2m Longevity boost for rapamycin Alzheimer’s study

Rapamycin human clinical trial aims to make progress on Alzheimer's therapy. A new $2m grant will enable a clinical trial to examine the effects of...

FDA approval for small molecule drug bodes well for Longevity

Roche, the world’s largest biotech company, has won approval from the FDA for an SMA drug. The race to take a therapy from lab to...

UNITY cuts lead program after clinical trial fail

Company to focus on ophthalmologic and neurologic programs as Phase 2 knee osteoarthritis clinical study fails to meet primary endpoint. Senolytic therapy developer UNITY...

Help us help you: Longevity biotech survey

A new survey on translational processes and hurdles to clinical trials in Longevity biotech. We're working with two MDs: Oliver Zolman and Jian Fransen, on...

Alkahest reveals clinical trial progress

Alkahest pipeline sees multiple therapeutic candidates progressing through clinical trials. Biopharmaceutical company Alkahest has released details of its progress on a range of therapeutic candidates;...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...

Easy-peasy Series-B(sy)

Nuritas launches PeptiYouth™ an AI-discovered peptide, clinically proven, anti-aging molecule. Nuritas, a leader in Artificial Intelligence-based peptide discovery, has launched PeptiYouth™, a peptide discovered within peas and which, following clinical trials, has been shown...

Machine learning to de-risk clinical trials

Insilico and Oxford University used machine learning to predict major clinical forms of drug cardiotoxicity. Insilico Medicine announced this week that they, in partnership with...

Move over AI? Here comes biological intelligence

Braincures raising funds to take-on AI drug discovery for Alzheimer’s and other neurological diseases with data analysis and systems biology. The treatment of neurological diseases...

New Japanese stem cell clinical trial for aging frailty

Longeveron announces Phase 2 clinical trial to evaluate the safety and efficacy of Mesenchymal Stem Cells (LMSCs) for the treatment of aging frailty in...

Alkahest announces phase 2 study treatment of cognitive impairment

Extra-corporeal medical device could improve neuro outlook for end-stage renal disease patients. Alkahest has announced its first foray into dialysis-associated dementia with a new randomised,...

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...

New young blood plasma research creates a stir

Indian start-up Nugenics Research to commercialise “Elixir” after showing 54% age reversal in animal study. The topic of using blood plasma to address human Longevity...

Latest articles

Peptide molecule causes cancer cells to self destruct

New breakthrough by a team led by eminent oncologist Loren Walensky brings new hope for future cancer treatments – and Longevity.  Everyone needs a way...

WHO portal brings aging data together

We live in a world driven by data and the World Health Organization (WHO) has now launched the first data portal to bring together...

The natural medicine war chest to fight aging

Quicksilver's liposomal delivery system boasts a non-invasion of the body patchers. Colorado-based Quicksilver Scientific manufactures a range of supplements from immunity boosters to NAD+. By...

Jim Mellon and Phil Newman: Longevity interviews

Master Investor is a publication that helps private investors to take charge of their financial destiny: covering a range of subjects, from shares to...